Clinical Development Expertise Aids IQVIA (IQV), Costs High

IQV has reported impressive first-quarter 2024 results. Adjusted earnings (excluding 98 cents from nonrecurring items) were $2.5 per share, which beat the Zacks Consensus Estimate by 2.8% and increased 3.7% from the year-ago reported figure. Total revenues of$ 3.7 billion surpassed the consensus estimate by 1.2% and grew 2.3% from the year-ago quarter. The company's addressable market size is more than $330 billion. It consists of outsourced research and development, real-world evidence and connected health ...